A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
Christoph Röllig(University Hospital Carl Gustav Carus), Michael Krämer(University Hospital Carl Gustav Carus), Reingard Stuhlmann(Asklepios Klinik St. Georg), Gerhard Ehninger(University Hospital Carl Gustav Carus), Silke Soucek(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Markus Schaich(Rems-Murr-Klinikum), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Martin Wermke(National Center for Tumor Diseases), H. Bodenstein(Pius Hospital Oldenburg), Walter E. Aulitzky(Robert Bosch Hospital), Friedrich Stölzel(German Cancer Research Center), Ulrich S. Schuler(University Hospital Carl Gustav Carus), Martin Gramatzki(University Hospital Schleswig-Holstein), Uwe Platzbecker(National Center for Tumor Diseases), Malte von Bonin(Städtisches Klinikum Dresden), Hannes Wandt(Nuremberg Hospital), Christian Thiede(University Hospital Carl Gustav Carus), Brigitte Mohr(Klinik und Poliklinik für Psychotherapie und Psychosomatik)
Cited by 177
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k